Screener / SEC EDGAR /CIK 0001722482 /10-K filed Feb 11, 2026, compared with Feb 7, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Technology · Lab Instruments

Avantor, Inc. AVTR

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 11, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

16.0% to -3.8% (-19.7 pts)

“Operating income declined largely due to a non‑cash goodwill impairment charge recorded in the Distribution reporting unit in the current year and the absence of the”

Read it in the 10-K

“In Corporate, Adjusted Operating Income decreased $4.0 million due to various immaterial factors.”

Read it in the 10-K

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-174.5%

The MD&A has no sentence that names a cause for this change.

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-25.8%

The MD&A has no sentence that names a cause for this change.

Gross margin

Change, FY to Dec 31, 2025 vs Dec 31, 2024

33.6% to 32.7% (-0.9 pts)

“Gross margin and gross profit decreased, reflecting lower sales volume, inflationary pressures, the divestiture of our Clinical Services business and higher freight costs.”

Read it in the 10-K

“Gross margin decreased 90 basis points primarily due to inflationary pressures, higher freight costs, unfavorable manufacturing variances, unfavorable product mix and the divestiture of our Clinical Services business, partially offset by lower inventory reserves.”

Read it in the 10-K

Revenue

Change, FY to Dec 31, 2025 vs Dec 31, 2024

-3.4%

“For the year ended December 31, 2025, net sales declined primarily due to the divestiture of our Clinical Services business within our Advanced Lab Services business and reduced customer demand in the Total Science Solutions business, both of which impacted the Laboratory Solutions segment.”

Read it in the 10-K

“The sales decline was primarily driven by decreased demand for consumables and equipment and instrumentation from our Total Science Solutions business due to the uncertainty around funding and increased competitive intensity.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 -3.4%

    “For the year ended December 31, 2025, net sales declined primarily due to the divestiture of our Clinical Services business within our Advanced Lab Services business and reduced customer demand in the Total Science Solutions business, both of which impacted the Laboratory Solutions segment.”

    Read it in the FY 2025 10-K

    “The sales decline was primarily driven by decreased demand for consumables and equipment and instrumentation from our Total Science Solutions business due to the uncertainty around funding and increased competitive intensity.”

    Read it in the FY 2025 10-K
  • FY 2024 -2.6%

    “In 2024, the net sales decline was driven by decreases in both segments primarily due to reduced customer demand.”

    Read it in the FY 2024 10-K

    “The sales decline was driven primarily by decreased demand in biopharma and healthcare end markets.”

    Read it in the FY 2024 10-K

Gross margin

2 of 2 years explained
  • FY 2025 -0.9 pts

    “Gross margin and gross profit decreased, reflecting lower sales volume, inflationary pressures, the divestiture of our Clinical Services business and higher freight costs.”

    Read it in the FY 2025 10-K

    “Gross margin decreased 90 basis points primarily due to inflationary pressures, higher freight costs, unfavorable manufacturing variances, unfavorable product mix and the divestiture of our Clinical Services business, partially offset by lower inventory reserves.”

    Read it in the FY 2025 10-K
  • FY 2024 -0.3 pts

    “Lower gross profit and higher annual incentive compensation expenses, partially offset by savings from our cost transformation initiative, drove Adjusted EBITDA and Adjusted Operating Income margin contraction.”

    Read it in the FY 2024 10-K

    “In 2024, gross margin decreased 30 basis points resulting primarily from the impact of inflationary pressures, partially offset by savings from our cost transformation initiative.”

    Read it in the FY 2024 10-K

Operating margin

2 of 2 years explained
  • FY 2025 -19.7 pts

    “Operating income declined largely due to a non‑cash goodwill impairment charge recorded in the Distribution reporting unit in the current year and the absence of the”

    Read it in the FY 2025 10-K

    “In Corporate, Adjusted Operating Income decreased $4.0 million due to various immaterial factors.”

    Read it in the FY 2025 10-K
  • FY 2024 +6.0 pts

    “In 2024, operating income increased primarily from the gain on sale of our Clinical Services business and the absence of impairment charges in 2024, partially offset by lower gross profit as previously discussed, higher operating expenses driven by restructuring and severance charges, transformation expenses, and annual incentive compensation expenses.”

    Read it in the FY 2024 10-K

    “In Corporate, Adjusted Operating Income decreased $8.0 million driven primarily by increased stock-based compensation expense.”

    Read it in the FY 2024 10-K

Net income

1 of 2 years explained
  • FY 2025 -174.5%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +121.6%

    “In 2024, net income increased primarily due to higher operating income, as previously discussed, as well as lower interest expense due to debt repayments on our variable-rate debt, partially offset by higher income tax expense due to higher income before income taxes.”

    Read it in the FY 2024 10-K

Cash from operations

1 of 2 years explained
  • FY 2025 -25.8%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 -3.4%

    “Cash flows from operating activities provided $29.2 million less cash in 2024 due to higher cash costs related to our cost transformation initiative and higher cash taxes paid in the current year, partially offset by improved working capital.”

    Read it in the FY 2024 10-K

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AVTR/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.